Strategies and Advancements in Harnessing the Immune System for Gastric Cancer Immunotherapy

<table class="table-group" id="tab2"><tr><td><table class="table"><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr class="thead"><td align="left">Target</td><td align="center">Agent</td><td align="center">Description </td></tr><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr><td align="left" rowspan="2">CTLA-4</td><td align="center">Ipilimumab</td><td align="center">Humanized IgG1 kappa</td></tr><tr><td align="center">Tremelimumab</td><td align="center">Fully human IgG2</td></tr><tr><td align="center" colspan="3"><hr/></td></tr><tr><td align="left" rowspan="2">PD-1</td><td align="center">Nivolumab</td><td align="center">Fully human IgG4</td></tr><tr><td align="center">Pembrolizumab</td><td align="center">Humanized IgG4</td></tr><tr><td align="center" colspan="3"><hr/></td></tr><tr><td align="left" rowspan="2">PD-L1</td><td align="center">MPDL3280A</td><td align="center">Human IgG1</td></tr><tr><td align="center">MEDI4736</td><td align="center">Human IgG1 kappa</td></tr><tr class="table-tr"><td colspan="3"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

Checkpoint inhibitors in gastric cancer immunotherapy.

Journal of Immunology Research

tab2

Table 2

Table 2: Strategies and Advancements in Harnessing the Immune System for Gastric Cancer Immunotherapy 